Phase I-II
A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors
- Study HIC#:2000038785
- Last Updated:03/13/2025
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
Contact Us
For more information about this study, including how to volunteer, contact:
Ingrid Palma
- Phone Number: 1-203-785-6431
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Eligibility Criteria
Inclusion Criteria
- Participants must have at least one measurable lesion per response evaluation criteria in solid tumors.
- Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
- Participants must have a life expectancy of at least 3 months at the time of the first dose.
Exclusion Criteria
- Participants must not have any mixed Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) histology.
- Participants must not have any untreated symptomatic central nervous system (CNS) metastases.
- Participants must not have a history of serious recurrent infections.
- Participants must not have a history of severe heart disease.
- Other protocol-defined Inclusion/Exclusion criteria apply.
